Get the Stockscreener App
8.81
3.72%
-0.34
After Hours:
8.90
0.09
+1.02%
Relay Therapeutics Inc stock is traded at $8.81, with a volume of 2.22M.
It is down -3.72% in the last 24 hours and up +12.95% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
See More
Previous Close:
$9.15
Open:
$9.14
24h Volume:
2.22M
Relative Volume:
0.96
Market Cap:
$1.53B
Revenue:
$25.55M
Net Income/Loss:
$-341.97M
P/E Ratio:
-3.1464
EPS:
-2.8
Net Cash Flow:
$-304.44M
1W Performance:
+8.10%
1M Performance:
+12.95%
6M Performance:
+162.99%
1Y Performance:
+134.31%
1-Day Range:
$8.35
$9.32
1-Week Range:
$8.33
$9.32
52-Week Range:
$1.775
$9.32
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
8.81 | 1.59B | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Dec-12-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Apr-17-25 | Initiated | Wells Fargo | Equal Weight |
| Sep-10-24 | Resumed | Goldman | Buy |
| Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-23 | Initiated | Raymond James | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Sep-30-22 | Initiated | Barclays | Equal Weight |
| Sep-02-22 | Initiated | Stifel | Buy |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Jul-21-21 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
| Nov-05-20 | Initiated | H.C. Wainwright | Buy |
| Aug-10-20 | Initiated | Cowen | Outperform |
| Aug-10-20 | Initiated | Goldman | Buy |
| Aug-10-20 | Initiated | Guggenheim | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
Relay Therapeutics stock hits 52-week high at $9.16 By Investing.com - Investing.com South Africa
Relay Therapeutics (NASDAQ:RLAY) Sets New 12-Month HighTime to Buy? - MarketBeat
Relay Therapeutics stock hits 52-week high at $9.16 - Investing.com
Assessing Relay Therapeutics (RLAY) Valuation After Recent Share Price Momentum And Price To Book Discount - Sahm
Assessing Relay Therapeutics (RLAY) Valuation After FDA Breakthrough Therapy Designation For Zovegalisib - Yahoo Finance
Relay Therapeutics Insider Sells 21,000 Shares for $166,700 After 65% Run - The Globe and Mail
$207B Market Shift: The Race for Fast Track Approval in Oncology - Investing News Network
$207B Market Shift: The Race for Fast Track Approval in Oncology - Benzinga
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - Investing News Network
Relay Thera’s zovegalisib wins ‘Breakthrough’ status from FDA - The Pharma Letter
Relay Therapeutics announces Zovegalisib granted therapy designation by FDA for PIK3CA-mutant - marketscreener.com
Relay Therapeutics stock rises after FDA grants Breakthrough Therapy status By Investing.com - Investing.com South Africa
Relay Therapeutics stock rises after FDA grants Breakthrough Therapy status - Investing.com
Relay Therapeutics Announces Breakthrough Therapy Designation for Zovegalisib - TradingView
Relay Therapeutics Announces Zovegalisib Granted - GlobeNewswire
FDA fast-tracks Relay drug for hard-to-treat advanced breast cancer - Stock Titan
Aug Retail: Can Relay Therapeutics Inc sustain its profitabilityProfit Target & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Oppenheimer Notes Relay Therapeutics, Inc. (RLAY) Pipeline Strength in Mutant-Selective Inhibitors - Finviz
Relay Therapeutics (NASDAQ:RLAY) Shares Up 7.2%Here's Why - MarketBeat
Oppenheimer Notes Relay Therapeutics (RLAY) Pipeline Strength in Mutant-Selective Inhibitors - Yahoo Finance
What Relay Therapeutics (RLAY)'s Zovegalisib Data and Insider Sales Mean For Shareholders - Sahm
Rate Cut: Is Relay Therapeutics Inc a speculative investmentPortfolio Gains Report & Consistent Profit Alerts - baoquankhu1.vn
Movement Recap: Will Relay Therapeutics Inc benefit from government policyWeekly Profit Recap & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Relay Therapeutics, Inc. (RLAY) Stock Analysis: Exploring an 88.66% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Relay Therapeutics (RLAY) Valuation Check After Analyst Upgrades And Zovegalisib Breast Cancer Data - Sahm
Relay Therapeutics president sells $166k in RLAY stock By Investing.com - Investing.com Australia
Moving Averages: Is Trex Company Inc stock a buy or sellTrade Analysis Summary & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Guidance Update: Can Relay Therapeutics Inc reach all time highs this year - baoquankhu1.vn
Relay Therapeutics (NASDAQ:RLAY) Insider Donald Bergstrom Sells 2,686 Shares - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Insider Sells $11,441.30 in Stock - MarketBeat
Insider Selling: Relay Therapeutics (NASDAQ:RLAY) CFO Sells 1,695 Shares of Stock - MarketBeat
Insider Selling: Relay Therapeutics (NASDAQ:RLAY) Insider Sells 11,684 Shares of Stock - MarketBeat
Thomas Catinazzo Sells 13,820 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock - MarketBeat
Rahmer Peter, chief corporate development officer at Relay Therapeutics, sells $100k in shares - Investing.com Canada
Relay Therapeutics president sells $166k in RLAY stock - Investing.com
Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 6.7%Should You Sell? - MarketBeat
Trend Recap: What is the Moat Score of REGNJuly 2025 Setups & Technical Pattern Alert System - baoquankhu1.vn
Oppenheimer Upgrade Fuels Relay Therapeutics Rally On Zovegalisib Optimism (NASDAQ:RLAY) - Seeking Alpha
Relay Therapeutics shares climb after Oppenheimer lifts rating - MSN
Relay Therapeutics (NASDAQ:RLAY) Trading Up 8.4%Here's Why - MarketBeat
Oppenheimer Upgrades Relay Therapeutics (RLAY) with Positive Out - GuruFocus
Oppenheimer Upgrades Relay Therapeutics (RLAY) - Nasdaq
Oppenheimer upgrades Relay Therapeutics stock rating on gedatolisib concerns By Investing.com - Investing.com Canada
Relay Therapeutics (RLAY) Upgraded by Oppenheimer, Price Target Set at $14.00 | RLAY Stock News - GuruFocus
Relay Therapeutics stock rises after Oppenheimer upgrade By Investing.com - Investing.com Nigeria
Relay Therapeutics stock rises after Oppenheimer upgrade - Investing.com
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):